Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM9BJD)

• Drug Name: Tisagenlecleucel Drug Info
• Synonyms: Tisagenlecleucel-T

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Approved	[1]
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[2]
Diffuse large B-cell lymphoma	2A81	Phase 3	[2]
Follicular lymphoma	2A80	Phase 2	[2]
Acute myeloid leukaemia	2A60	Application submitted	[3]

• Cross-matching ID: TTD Drug ID: DMM9BJD

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[5]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[6]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[7]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[8]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[9]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[10]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[11]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[12]
CD19 CAR T cells	DM32148	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[13]

Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[14]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[15]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[16]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[17]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[18]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[16]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[19]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[20]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[21]
Ocrelizumab	DMEZ2KH	Diffuse large B-cell lymphoma	2A81	Approved	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Immunostimulant	[1]
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Immunostimulant	[3]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [9] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [10] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [11] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [12] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [13] ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma
• [14] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [15] Clinical pipeline report, company report or official report of Genmab.
• [16] Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
• [17] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [18] The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [20] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [21] Clinical pipeline report, company report or official report of Genentech (2009).
• [22] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.